Assessment of arterial rigidity on background of chemotherapy of breast cancer: opportunities and prospects


DOI: https://dx.doi.org/10.18565/therapy.2020.4.131-141

Medvedeva E.G., Yuschuk E.N., Ivanova S.V., Sadulaeva I.A., Trofimenko O.S., Scherbak M.M.

A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia
According to world statistics, breast cancer is the leading cause of death among neoplasms in women. Every year, socio-economic significance of this disease increases, due to disability and premature death of these patients. Modern antineoplasmatic therapy has increased the survival rate of this group of patients, but gave rise to the increase to number of early and distant cardiovascular complications (CVC), thereby increasing the percentage of deaths from cardiovascular diseases. This was the reason for the development of guidelines for monitoring and prevention of cardiotoxic complications caused by chemotherapy, while the negative impact of chemotherapy drugs on the vascular wall to this day remains completely unexplored. One promising marker of the vascular wall damage is arterial stiffness, an integral indicator that has proven to be a prognostically significant and independent predictor of CVC. The purpose of this review is to describe the most common methods of determining vascular stiffness in clinical practice, analyze the results of their application in patients with breast cancer, and to discuss promising directions for early detection and prevention of vascular complications in this category of patients.
Keywords: arterial rigidity, vasculotoxicity, breast cancer, chemotherapy, anthracyclines
Read entire article

Literature


  1. Чиссов В.И., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). М.: ФГБУ «МНИОИ им. ПА Герцена» Минздравсоцразвития России, 2012; с. 12.1. [Chissov V.I., Starinsky V.V., Petrova G.V. Malignant neoplasms in Russia in 2010 (morbidity and mortality). M.: FGBU «MNIOI im. PA Gercena» Minzdravsocrazvitiya Rossii. 2012; p. 12.1. (In Russ.)]

  2. Одинцова И.Н., Писарева Л.Ф., Хряпенков А.В. Эпидемиология злокачественных новообразований в мире. Сибирский онкологический журнал. 2015; 5: 95–101. [Odintsova I.N., Pisareva L.F., Khryapenkov A.V. Worldwide cancer epidemiology. Siberian journal of oncology. 2015; 5: 95–101 (In Russ.)].

  3. American Cancer Society. Breast Cancer Facts & Figures 2019–2020. Atlanta: American Cancer Society, Inc. 2019.

  4. Sharma A.V., Reddin G., Forrestal B., Barac A. Cardiovascular disease risk in survivors of breast cancer. Curr Treat Options Cardiovascular Med. 2019; 21(12): 79. doi: 10.1007/s11936-019-0788-2

  5. Болотина Л.В., Овчинников А.Г. Проблемы сердечно-сосудистых осложнений, индуцированных химиотерапией и таргетными препаратами. Исследования и практика в медицине. 2015; 4: 106–114. [Bolotina L.V., Ovchinnikov A.G. Cardiovascular complications caused by chemotherapy and targeted agents. Issledovaniya i praktika v meditsine. 2015; 4: 106–114 (In Russ.)]. doi: 10.17709/2409-2231-2015-2-4-77

  6. Herrmann J., Lerman A., Sandhu N.P. et al. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014; 89(9): 1287–306. doi: 10.1016/j.mayocp.2014.05.013.

  7. Ewer M.S., Ewer S.M. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015; 12(9): 547–58. doi: 10.1038/nrcardio.2015.65.

  8. Bradshaw P.T., Stevens J., Khankari N. et al. Cardiovascular disease mortality among breast cancer survivors. Epidemiology. 2016; 27(1): 6–13. doi: 10.1097/EDE.0000000000000394.

  9. Zamorano J.L., Lancellotti P., Rodriguez Munoz D. et al. (2016). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur Heart J. 2016; 37(36): 2768–801. doi: 10.1093/eurheartj/ehw211.

  10. Herrmann J., Yang E.H., Iliescu C.A. et al. Vascular toxicities of cancer therapies: the old and the new an evolving avenue. Circulation. 2016; 133(13): 1272–89. doi: 10.1161/CIRCULATIONAHA.115.018347.

  11. Васюк Ю.А., Иванова С.В., Школьник Е.Л. с соавт. Согласованное мнение российских экспертов по оценке артериальной жесткости в клинической практике. Кардиоваскулярная терапия и профилактика. 2016; 2: 4–19. [Vasyuk Yu.A., Ivanova S.V., Shkolnik E.L. et al. Consensus of Russian experts on the evaluation of arterial stiffness in clinical practice. Kardiovaskulyarnaya terapiya i profilaktika. 2016; 2: 4–19 (In Russ.)] doi: 10.15829/1728-8800-2016-2-4-19.

  12. Алиева А.С., Бояринова М.А., Орлов А.В. с соавт. Сравнительный анализ методов диагностики субклинического поражения сосудов (на примере выборки эпидемиологического исследования ЭССЕ-РФ). Российский кардиологический журнал. 2016; 6: 20–26. [Alieva A.S., Boyarinova M.A., Orlov A.V. et al. Comparative analysis of diagnostic methods for subclinical vessels lesion (under the cohort of epidemiological study ESSE-RF). Rossiysky kardiologichesky zhurnal. 2016; 6: 20–26 (In Russ.)] doi: 10.15829/1560-4071-2016-6-20-26.

  13. Bar-Joseph H., Stemmer S.M., Tsarfaty I. et al. Chemotherapy-induced vascular toxicity-real-time in vivo imaging of vessel impairment. J Vis Exp. 2015; 95: e51650. doi: 10.3791/51650.

  14. Котовская Ю.В. Центральная пульсовая волна: патофизиология и клиническое значение. Кардиология: новости, мнения, обучение. 2013; 1: 34–42. [Kotovskaya Yu.V. Central pulse wave: pathophysiology and clinical significance. Kardiologiya: novosti, mneniya, obuchenie. 2013; 1: 34–42 (In Russ.)].

  15. Милягин В.А., Комиссаров В.Б. Современные методы определения жесткости сосудов. Артериальная гипертензия. 2010; 2: 134–143. [ Milyagin V.A., Komissarov V.B. Modern methods for determining stiffness of blood vessels. Arterial’naya gipertenziya. 2010; 2: 134–143 (In Russ.)].

  16. Van Bortel L.M., Laurent S., Boutouyrie P. et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012; 30(3): 445–48. doi: 10.1097/HJH.0b013e32834fa8b0.

  17. Chaosuwannakit N., D’Agostino R. Jr, Hamilton C.A. et al. Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol. 2010; 28(1): 166–72. doi: 10.1200/JCO.2009.23.8527.

  18. Drafts B.C., Twomley K.M., D’Agostino R. Jr et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging. 2013; 6(8): 877–85. doi: 10.1016/j.jcmg.2012.11.017.

  19. Mizia-Stec K., Goscinska A., Mizia M. et al. Anthracycline chemotherapy impairs the structure and diastolic function of the left ventricle and induces negative arterial remodeling. Kardiol Pol. 2013; 71(7): 681–90. doi: 10.5603/KP.2013.0154.

  20. Grover S., Lou P.W., Bradbrook C. et al. Early and late changes in markers of aortic stiffness with breast cancer therapy. Internal medicine journal. 2015; 45(2): 140–47. doi: 10.1111/imj.12645.

  21. Yersal O., Eryilmaz U., Akdam H. et al. Arterial Stiffness in breast cancer patients treated with anthracycline and trastuzumab-based regimens. Cardiol Res Pract. 2018; 2018: 5352914. doi: 10.1155/2018/5352914.

  22. Souza C.A., Simoes R., Gomes Borges K.B. et al. Arterial stiffness use for early monitoring of cardiovascular adverse events due to anthracycline chemotherapy in breast cancer patients. A Pilot Study. Arq Bras Cardiol. 2018; 111(5): 721–28. doi: 10.5935/abc.20180168.

  23. Филатова А.Ю., Виценя М.В., Потехина А.В. с соавт. Атеросклероз брахиоцефальных артерий и артериальная жесткость у больных раком молочной железы. Кардиология. 2019; 1S: 43–52. [Filatova A.Y., Vitsenya M.V., Potekhina A.V. et al. Atherosclerosis of brachiocephalic arteries and arterial stiffness in patients with breast cancer. Kardiologiya. 2019; 1S: 43–52 (In Russ.)]. doi: 10.18087/cardio.2585.

  24. Koelwyn G.J., Lewis N.C., Ellard S.L. et al. Ventricular-arterial coupling in breast cancer patients after treatment with anthracycline-containing adjuvant chemotherapy. Oncologist. 2016; 21(2): 141–49. doi: 10.1634/theoncologist.2015-0352.

  25. Jenei Z., Bardi E., Magya M.T. et al. Anthracycline causes impaired vascular endothelial function and aortic stiffness in long term survivors of childhood cancer. Pathol Oncol Res. 2013; 19(3): 375–83. doi: 10.1007/s12253-012-9589-6.

  26. Budinskaya K., Puchnerova V., Svacinova J. et al. Non-invasive assessment of vascular system function and damage induced by anthracycline treatment in the pediatric cancer survivors. Physiol Res. 2017; 66(Suppl 4): S553–S560. doi: 10.33549/physiolres.933794.

  27. Mehta L.S., Watson K.E., Barac A. et al. Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association. Circulation. 2018; 137(8): e30–e66. doi: 10.1161/CIR.0000000000000556.

  28. Ben-Shlomo Y., Spears M., Boustred C. et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol. 2014; 63(7): 636–46. doi: 10.1016/j.jacc.2013.09.063.

  29. Mozos I., Luca C.T. Crosstalk between oxidative and nitrosative stress and arterial stiffness. Current vascular pharmacology. 2017; 15(5): 446–56. doi: 10.2174/1570161115666170201115428.

  30. Степанова Т.В., Иванов А.Н., Попыхова Э.Б., Лагутина Д.Д. Молекулярные маркеры эндотелиальной дисфункции. Современные проблемы науки и образования. 2019; 1: 37. [Stepanova T.V., Ivanov A.N., Popykhova E.B., Lagutina D.D. Molecular markers of endothelial dysfunction. Sovremennye problemy nauki i obrazovaniya. 2019; 1: 37 (In Russ.)].

  31. Chen J.J., Wu P.-T., Middlekauff H.R., Nguyen K.-L. Aerobic exercise in anthracycline-induced cardiotoxicity: a systematic review of current evidence and future directions. Am J Physiol Heart Circ Physiol. 2017; 312(2): H213–H222. doi: 10.1152/ajpheart.00646.2016.

  32. Pereira T., Santos F., Cipriano I. Effects of a personalized physical exercise program in the arterial stiffness in older adults. Artery Research. 2019; 25: 57–64. doi: 10.2991/artres.k.191126.001.

  33. Do J., Cho Y., Jeon J. Effects of a 4-week multimodal rehabilitation program on quality of life, cardiopulmonary function, and fatigue in breast cancer patients. J Breast Cancer. 2015; 18(1): 87–96. doi: 10.4048/jbc.2015.18.1.87.

  34. Baumann F.T., Bieck O., Oberste M. et al. Sustainable impact of an individualized exercise program on physical activity level and fatigue syndrome on breast cancer patients in two German rehabilitation centers. Support Care Cancer. 2017; 25(4): 1047–54. doi: 10.1007/s00520-016-3490-x.

  35. Leclerc A.F. Foidart-Dessalle M., Tomasella M. et al. Multidisciplinary rehabilitation program after breast cancer: benefits on physical function, anthropometry and quality of life. Eur J Phys Rehabil Med. 2017; 53(5): 633–42. doi: 10.23736/S1973-9087.17.04551-8.


About the Autors

Elizaveta G. Medvedeva, postgraduate student of the Department of clinical functional diagnostics of A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (916) 329-23-61. E-mail: elizavetapril@gmail.com. ORCID ID: https://orcid.org/0000-0002-5011-5346
Elena N. Yuschuk, MD, professor, head of the Department of clinical functional diagnostics of A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (916) 677-71-02. E-mail: ndlena@mail.ru. ORCID ID: https://orcid.org/0000-0003-0065-5624
Svetlana V. Ivanova, MD, professor of the Department of clinical functional diagnostics of A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (916) 187-41-73. E-mail: svivanova@rambler.ru. ORCID ID: https://orcid.org/0000-0001-7370-9297
Irina A. Sadulaeva, PhD, associate professor of the Department of clinical functional diagnostics of A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (926) 220-29-99. E-mail: sadvas@mail.ru. ORCID ID: https://orcid.org/0000-0002-9278-2008
Olga S. Trofimenko, PhD, assistant of the Department of clinical functional diagnostics of A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (903) 143-72-45. E-mail: troff45@mail.ru. ORCID ID: https://orcid.org/0000-0002-5648-672X
Mikhail M. Scherbak, assistant of the Department of clinical functional diagnostics of A.I. Yevdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia. Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (916) 809-28-64. E-mail: sheka2820mix@yandex.ru. ORCID ID: https://orcid.org/0000-0002-3747-0861

Back to Content

Бионика Медиа